Teva's Head of R&D Departs Abruptly for New Opportunity
Dr. Arik Yoz, Teva's Chief Medical Officer and Head of Global R&D, has resigned to accept an external offer, with his departure effective immediately. Dr. David Gardiner will serve as interim replacement while Teva searches for a permanent successor. The company affirmed its strategic direction and revenue projections remain unchanged. Yoz joined Teva in 2022 and was responsible for a large R&D division.
הידיעה ב-5 שורות · תקציר של baba
- Dr. Arik Yoz, Teva's Chief Medical Officer and Head of Global R&D, has resigned.
- His departure is effective immediately, though he will assist with the transition.
- Dr. David Gardiner will serve as interim replacement for the R&D leadership role.
- Teva stated its strategy and revenue projections remain unchanged by the resignation.
- Yoz joined Teva in August 2022 and previously worked at Vertex and Novartis.
Dr. Arik Yoz, Teva Pharmaceutical Industries' Chief Medical Officer and Head of Global R&D, has resigned from his position, effective immediately. The company announced his departure on Wednesday, stating that Yoz decided to accept an offer from outside Teva. He will remain with the company for a few months to assist with the transition.
Dr. David Gardiner, head of original drugs and clinical development, will serve as interim replacement. Teva has initiated a search for a permanent successor. The company emphasized that its strategy remains unchanged and reiterated its projection of $6-7 billion in revenue from its original drugs by 2030.
Yoz joined Teva in August 2022, during the tenure of former CEO Kare Schultz. He was responsible for the discovery, development, medical management, and safety of Teva's generic, biosimilar, and original drugs, overseeing a department of 4,100 employees. Prior to Teva, Yoz held senior roles at Vertex and Novartis and holds medical doctorates from the University of Yale School of Medicine.
Richard Francis, Teva's President and CEO, acknowledged Yoz's significant contributions to Teva and its R&D organization, particularly in building the product pipeline presented at a recent R&D day. Francis stated that Teva's strategy, priorities, and outlook remain consistent, with a focus on meeting commitments and advancing its innovative drug pipeline.
Dr. Yoz expressed pride in the R&D organization's achievements and the strong team built, highlighting the progress showcased at the R&D day as a reflection of the organization's strength and the science developed. He thanked the team for their dedication, talent, and partnership.
מוזכרים
אותו אירוע, כפי שכל מערכת דיווחה עליו בנפרד. פתחו כמה דיווחים כדי להשוות מה כל מערכת מדגישה, ומה היא משאירה בחוץ.
אחרים 2